Allergen immunotherapy: Guidelines, update, and recommendations of the World Health Organization

Allergen immunotherapy (AIT) is the administration of increasing doses of a n allergen vaccine to an allergic subject in order to reach a dose effectiv e to improve symptoms associated with subsequent exposure to the causative allergen. This form of therapy is effective in the treatment of allergic rh initis/conjunctivitis, allergic reactions to stinging insects, and allergic asthma. It is the only therapeutic modality that can affect the natural co urse of allergic diseases, and may prevent the development of asthma in pat ients with allergic rhinitis. AIT is indicated for patients with demonstrat ed specific IgE antibodies against clinically relevant allergens. The mixtu re of allergens to be utilized is based on the patient's history and skin a nd laboratory tests. The major risk of AIT is anaphylaxis. Such therapy is continued for three to five years, but the decision to discontinue it shoul d be individualized. interpretation of the history, physical findings, and skin and laboratory tests, the prescription and administration of allergen immunotherapy, its integration into the patient's treatment plan, and the d ecision to discontinue it require qualifying experience provided by special ist training in allergy and immunology.